Combination therapy with anti-PD-1 antibody, radiotherapy, and tyrosine kinase inhibitor for unresectable primary ectopic hepatocellular carcinoma: a case report with genomic profiling and literature review - Top-Institutions - MDSpire

Combination therapy with anti-PD-1 antibody, radiotherapy, and tyrosine kinase inhibitor for unresectable primary ectopic hepatocellular carcinoma: a case report with genomic profiling and literature review

  • By

  • Peng Tang

  • Weixing Liu

  • Yating Xu

  • You Long

  • Yixiao Li

  • Jiaxin Li

  • Mingheng Liao

  • Xin Wang

  • Jin Zhou

  • Yong Zeng

  • July 14, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Hepatocellular Carcinoma
    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Hepatocellular Carcinoma
    • Oncology

  • #3

    Sun Yat-sen University Cancer Center
    Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong

    Key Differentiators

    • Hepatocellular Carcinoma
    • Oncology

Original Source(s)

Combination therapy with anti-PD-1 antibody, radiotherapy, and tyrosine kinase inhibitor for unresectable primary ectopic hepatocellular carcinoma: a case report with genomic profiling and literature review

  • by Peng Tang, Weixing Liu, Yating Xu, You Long, Yixiao Li, Jiaxin Li, Mingheng Liao, Xin Wang, Jin Zhou, Yong Zeng

  • July 14, 2026

Related Content

One-carbon metabolism in cancer immunity: T-cell fitness, epigenetic programming, and therapeutic opportunities

A network meta-analysis of endocrine adverse events induced by immune checkpoint inhibitors in colorectal cancer

Inside VIVEbiotech’s Work with Zelluna on TCR-NK Cell Therapy

VIVEbiotech CEO Jon Alberdi lifts the lid on an eight-year collaboration focused on GMP lentiviral vectors for off-the-shelf solid tumor therapies

  • July 14, 2026

  • 4 min